COVID-19 R&D APPLICATIONS EVALUATED, CONTRACTS ARE BEING SIGNED
Until today LVPA has signed 21 financing contracts with companies implementing projects. Amounts vary from EURE 46,000 to 1 m.
„This project aims to encourage companies to invest in R&D helping to deal with problems and risks caused by COVID-19 pandemic. We see that contracts are being signed fast and some project are already being implemented“, – comments LVPA director Aurimas Želvys.
He also emphasizes that project requires to create and certify new products no later than December 31, 2021, and later project results have to generate income.
„Products and technologies necessary to manage the pandemic – medicines, means of diagnostics, medical equipment, personal protection means and disinfectants - are being created“, – claims Inga Lukošiūnaitė, acting head of LVPA science and innovation projects unit.